One very interesting comment in the article from a physician/scientist --
Researchers have been looking — without success — at targeted ways to dampen immune responses in critically ill people for decades, says Angus. “And we have 20 to 30 years of failing to improve outcome with therapies that try to block the cytokine cascade.”
This really tells you how big MSB's program is -- success would be a game changer for the treatment of inflammation.
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-197
-
- There are more pages in this discussion • 196 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
0.030(3.19%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 98.0¢ | 92.0¢ | $3.342M | 3.477M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 33313 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 73982 | 2 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |